Filtered By:
Infectious Disease: Coronavirus
Countries: Japan Health

This page shows you your search results in order of date.

Order by Relevance | Date

Total 23 results found since Jan 2013.

How do bats live with so many viruses? New bat stem cells hint at an answer
Compared with other mammals, bats are notorious for hosting more viruses that are dangerous to people but not themselves. It’s an oddity that’s drawn renewed attention since COVID-19 broke out in humans—many scientists suspect the coronavirus SARS-CoV-2 leaped from bats into people, directly or via an intermediate host. Seeking to create large quantities of bat tissue to help study why the flying animals are so virus-friendly, a research team now reports it has transformed adult bat cells into versatile stem cells that can be coaxed to form many kinds of tissue . The advance, described today in Cell ...
Source: Science of Aging Knowledge Environment - February 21, 2023 Category: Geriatrics Source Type: research

‘Extremely satisfying’: Scientist’s insight powers new RSV vaccine for infants
Barney Graham, a former scientist at the U.S. National Institute of Allergy and Infectious Diseases (NIAID), was thrilled yesterday when Pfizer announced encouraging results from an experimental vaccine that could protect against a major childhood killer. In a press release, the company said immunizing pregnant women * with its vaccine against respiratory syncytial virus (RSV) protected their babies from severe disease for 6 months. If the full results of its clinical trial bear out that promise, the vaccine could spare millions of infants worldwide from RSV-related hospitalization, reduce lasting lung damage f...
Source: Science of Aging Knowledge Environment - November 2, 2022 Category: Geriatrics Source Type: research

U.S. weighs crackdown on experiments that could make viruses more dangerous
.news-article__hero--featured .parallax__element{ object-position: 50% 40%; -o-object-position: 50% 40%; } .scroll-wrapper { overflow-x: auto; } .scroll-wrapper .news-article__figure__image{ width: 2680px; max-width: none; padding-bottom: .75rem; } .scroll-fade-before, .scroll-fade-after { position: absolute; width: 1.5rem; transition-duration: .1s; opacity: 1; } .scroll-fade-before { left: 1rem; /*margin-left: -1px;*/ background: linear-gradient(90deg, #fff, #fff 35%, hsla(0, 0%, 100%, 0)); } .scroll-fade-after { right: 1rem; /*margin-right: -1px;*/ background: linear-gradient(270deg, #fff, #fff 35%, hsla(0,...
Source: ScienceNOW - October 19, 2022 Category: Science Source Type: news

Third person dies in Japan after taking contaminated Moderna coronavirus vaccine
A 49-year-old man died the day after taking his second shot of the vaccine, though authorities said a causal link has not been identifiedSee all our coronavirus coverageA third man has died in Japan after receiving an injection from one of three batches of Moderna vaccines since identified as contaminated, though authorities say no causal link has yet been found.The 49-year-old man had his second shot on 11 August and died the following day. His only known health issue was an allergy to buckwheat, the health ministry said on Monday. As with theprevious two deaths, the ministry said it had yet to establish if the latest fat...
Source: Guardian Unlimited Science - September 7, 2021 Category: Science Authors: Gavin Blair in Tokyo Tags: Japan Coronavirus Vaccines and immunisation Science Asia Pacific Source Type: news

Psychogenic fever due to worry about COVID ‐19: A case report
Psychogenic fever worrying about COVID-19 is an attentional differential diagnosis in the era of COVID-19. Typical cases should be treated with an anxiolytic. AbstractPsychogenic fever is stress-related hyperthermia that is recognized as a psychosomatic condition. We treated a 46-year-old Japanese man who was worrying about the coronavirus infection (COVID-19) and had a fever with a maximum temperature of 38.1 ℃. The patient was tested twice for SRAS-CoV-2 using polymerase chain reaction (PCR), but both tests were negative. All tests were negative for organic diseases, including infections, allergy/collagen diseases, end...
Source: Clinical Case Reports - August 16, 2021 Category: General Medicine Authors: Osamu Imataki, Makiko Uemura Tags: CASE REPORT Source Type: research

Regulation of the Expression of SARS-CoV-2 Receptor Angiotensin-Converting Enzyme 2 in Nasal Mucosa
CONCLUSION: Inflammatory endotype affects ACE2 expression in the nasal mucosa and influences susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In particular, type 2 inflammation could downregulate ACE2 expression in the nasal mucosa and reduces susceptibility to SARS-CoV-2 in patients with CRSwNP. Although in vivo experiments are required, administration of SCFAs to the nasal cavity might be worthy of consideration as a preventative or therapeutic strategy for the early-stage COVID-19.PMID:34232770 | DOI:10.1177/19458924211027798
Source: American Journal of Rhinology and Allergy - July 7, 2021 Category: ENT & OMF Authors: Tetsuji Takabayashi Kanako Yoshida Yoshimasa Imoto Robert P Schleimer Shigeharu Fujieda Source Type: research

The Great Vaccine Race: Inside the Unprecedented Scramble to Immunize the World Against COVID-19
The cleverest of enemies thrive on surprise attacks. Viruses—and coronaviruses in particular—know this well. Remaining hidden in animal hosts for decades, they mutate steadily, sometimes serendipitously morphing into more effective and efficient infectious agents. When a strain with just the right combination of genetic codes that spell trouble for people makes the leap from animal to human, the ambush begins. Such was the case with SARS-CoV-2, the coronavirus behind COVID-19, and the attack was mostly silent and insidious at first. Many people infected with SARS-CoV-2 remained oblivious as they served as the v...
Source: TIME: Health - September 10, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Magazine Source Type: news

Why the U.S. Is Losing the War On COVID-19
It is a frightening time to live in the United States. COVID-19, a novel disease as ruthless as it is seemingly random, is picking us off by the thousands; even many of those who “recover” may never truly be the same again. The pandemic has exposed the gulf between what this country promises for its citizens and what it actually delivers. And as the U.S. barrels toward Election Day, the outbreak is sure to complicate the voting process, with potentially disastrous results. For a short time in the spring, it appeared the U.S. was getting a grip on its outbreak. Hard-hit states like New York successfully flattene...
Source: TIME: Science - August 13, 2020 Category: Science Authors: Alex Fitzpatrick Tags: Uncategorized COVID-19 UnitedWeRise20Disaster Source Type: news

‘ Genuine Evidence Of Improvement ’ : Remdesivir Helped Some Coronavirus Patients In Study
(CNN) — A five-day course of the antiviral drug remdesivir sped recovery in moderately ill patients with pneumonia from Covid-19, drugmaker Gilead Sciences announced in a statement Monday. It’s more evidence that the drug can help patients, however outside experts are not calling this a “game changer” quite yet. Coronavirus patients who were hospitalized, but not sick enough to need oxygen from a ventilator, were more likely to recover after a five-day course of remdesivir than those given the current standard of care alone, Gilead said. The results from the Phase III clinical trial on the drug have...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - June 2, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health CNN Coronavirus remdesivir Source Type: news

How Remdesivir Moved From Back Shelf to Best Hope for Treating COVID-19
This study showed that a five-day regimen is as effective as 10 days–that’s important, doctors say, since it could mean shorter stays in the hospital, which could alleviate some of the burden on the health care system. “Of course we will have to wait for the final review of all the data, but it would be very nice to have an anti-viral that’s efficacious in this terrible illness,” says Dr. Aruna Subramanian, a clinical professor of medicine at Stanford and an investigator on the study. “At least we know that we can help patients with this, and that’s really the bottom line.” T...
Source: TIME: Health - May 21, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 feature Magazine Source Type: news

Here ’s How Scientists and Public-Health Experts Recommend the U.S. Gets Back to ‘Normal’
There is both promise and peril in being a pioneer, and the people of Hokkaido have learned both lessons well over the past few months. After infections of COVID-19 on the Japanese island exploded following its annual winter festival this year, officials in February declared a state of emergency to control the disease. Soon after, new daily cases plummeted, and Hokkaido’s quick action was heralded as a beacon for the rest of Japan to follow. But it wasn’t just infections that dropped; over the next month, agriculture and tourism business also dried up, and Hokkaido’s governor decided to ease social restri...
Source: TIME: Health - April 30, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Magazine Source Type: news

Vaccines, Antibodies and Drug Libraries. The Possible COVID-19 Treatments Researchers Are Excited About
In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19. It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18...
Source: TIME: Health - April 14, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

All Your Coronavirus Questions, Answered
One of the worst symptoms of any plague is uncertainty—who it will strike, when it will end, why it began. Merely understanding a pandemic does not stop it, but an informed public can help curb its impact and slow its spread. It can also provide a certain ease of mind in a decidedly uneasy time. Here are some of the most frequently asked questions about the COVID-19 pandemic from TIME’s readers, along with the best and most current answers science can provide. A note about our sourcing: While there are many, many studies underway investigating COVID-19 and SARS-CoV-19, the novel coronavirus that causes the illn...
Source: TIME: Health - April 14, 2020 Category: Consumer Health News Authors: TIME Staff Tags: Uncategorized COVID-19 Explainer Source Type: news

What the U.S. Needs to do Today to Follow South Korea ’s Model for Fighting Coronavirus
The United States has a narrow window of opportunity to determine the fate of its coronavirus crisis. Will we end up looking like Italy or South Korea? Italy’s health system has imploded under the strain of new cases and the shortage of ventilators means doctors must make agonizing decisions on who to save and who to let die. In contrast, South Korea acted swiftly and boldly to “flatten the curve”— the government did everything it could to slow the rate of increase and so reduce the burden of the illness on the country’s clinics and hospitals. Right now, the number of new cases of confirmed in...
Source: TIME: Health - March 17, 2020 Category: Consumer Health News Authors: Gavin Yamey Tags: Uncategorized COVID-19 Source Type: news